Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02311816

Enrollment

114

Registered

2014-12-08

Start date

2012-10-31

Completion date

2013-10-31

Last updated

2014-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infection

Keywords

Bacterial infection, empiric antibiotic therapy

Brief summary

The value of procalcitonin change from the day before to the day when infection was suspected in predicting bacterial infection in intensive care patients.

Detailed description

Starting antibiotic therapy early in critically ill patients with suspected infection is of utmost importance with significant effect on survival. Procalcitonin is a reliable sepsis marker but results about its usefulness in initiating antimicrobials are conflicting. Our aim is to investigate the predictive value of 24 hours procalcitonin kinetics before starting empirical antibiotic therapy in intensive care patients as an indicator of the presence of bacterial infection.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical signs of infection * Suspected or proven acute infection requiring empiric antibiotic therapy as decided by the attending ICU physician * Microbiological sample sent for staining * Inflammatory markers available from the previous day

Exclusion criteria

* Patients younger than 18 years * Who received prophylactic or empiric antibiotic therapy 48 hours before inclusion * Whose receiving acute renal replacement therapy in the first 24 hours following antibiotic treatment * Following cardiopulmonary resuscitation * End stage diseases with a do not resuscitate order * Immunocompromised patients (human immunodeficiency virus infection, bone marrow transplantation, malignant haematological disorders and chemotherapy) * Post cardiac surgery patients

Design outcomes

Primary

Measure	Time frame	Description
Procalcitonin kinetic	24 hours before starting empiric antibiotic treatment	Procalcitonin levels are measured at starting empiric antibiotic treatment and 24 hours before. The changes in percentage are calculated form the day before and right before the first exposition of the antibiotic therapy.

Secondary

Measure	Time frame	Description
C-reactive protein kinetic	24 hours before starting empiric antibiotic treatment	C-reactive protein levels are measured at starting empiric antibiotic treatment and 24 hours before. The changes in percentage are calculated form the day before and right before the first exposition of the antibiotic therapy.
Body temperature kinetic	24 hours before starting empiric antibiotic treatment	Body temperatures are measured at starting empiric antibiotic treatment and 24 hours before. The changes in percentage are calculated form the day before and right before the first exposition of the antibiotic therapy.
White blood cell count kinetic	24 hours before starting empiric antibiotic treatment	White blood cell count levels are measured at starting empiric antibiotic treatment and 24 hours before. The changes in percentage are calculated form the day before and right before the first exposition of the antibiotic therapy.

Countries

Hungary

Outcome results